Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2

Blood

Volumn 117, Issue 6, 2011, Pages 2075-2076

  Schaub, Franz X ^a   Lehmann, Thomas ^a   Looser, Renate ^a   Hao Shen, Hui ^a   Tichelli, Andre ^a   Skoda, Radek C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

FOLLOW UP; GENE; GENE MUTATION; HEMATOPOIETIC STEM CELL; HETEROZYGOSITY LOSS; HOMOZYGOSITY; LETTER; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; TET2 GENE;

EID: 79951547612     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-316471     Document Type: Letter

References (5)

1. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
2. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009;41(7):838-842.
3. Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115(10):2003-2007.
4. Kiladjian JJ, Masse A, Cassinat B, et al. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia. 2010;24(8):1519-1523.
5. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010;466(7310):1129-1133.